Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2021-11-23 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY NMPA FOR A PHASE III CLINICAL TRIAL OF KN046 FOR THE TREATMENT OF ADVANCED PDAC
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Alphamab Oncology regarding the approval of an investigational new drug (IND) by the National Medical Products Administration (NMPA) for a Phase III clinical trial. It is an announcement of a business development event rather than a financial report or regulatory filing. The document does not contain financial statements, audit information, or detailed management discussion. It is not a report of voting results, nor a call transcript or capital update. The content focuses on clinical trial progress and company business updates, typical of a voluntary announcement. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-11-23 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2021
Regulatory Filings Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on share capital, issued shares, share options, and confirmations related to securities issued by Alphamab Oncology. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content includes detailed tables on authorized and issued shares, share options, and confirmations by an executive director. There is no indication that this is an annual or interim financial report, earnings release, or management discussion. Instead, it is a regulatory filing related to share capital movements and confirmations required by the stock exchange. The document length (8001 characters) and detailed nature support it being a regulatory filing rather than a brief announcement or a full financial report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-11-04 English
VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF COMMERCIAL OFFICER
Board/Management Information Classification · 100% confidence The document is a voluntary announcement from Alphamab Oncology regarding the appointment of a new Chief Commercial Officer. It contains biographical details of the appointee and a formal welcome from the Board. There is no financial data, no report attached or referenced, and no mention of regulatory filings or voting results. The content clearly relates to a change in senior management. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is short (3105 characters), consistent with an announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2021-11-02 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE II/III CLINICAL TRIAL OF KN046 IN COMBINATION WITH LENVATINIB FOR THE TREATMENT OF PD-(L)1 REFRACTORY ADVANCED NSCLC
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Alphamab Oncology regarding the dosing of the first patient in a Phase II/III clinical trial for a drug candidate. It is an update on business progress and clinical development, not a financial report or regulatory filing. The text includes no financial data, no voting results, no management changes, no audit information, and no earnings data. It is a business progress announcement related to clinical trials and drug development. Such announcements typically fall under general regulatory announcements or voluntary business updates. Given the absence of financial or regulatory report content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2021-10-28 English
GRANT OF SHARE OPTIONS
Share Issue/Capital Change Classification · 100% confidence The document is an announcement regarding the grant of share options to employees under a share option scheme. It includes details such as the date of grant, exercise price, number of options granted, validity period, and vesting schedule. It is made pursuant to a listing rule and is a formal disclosure to the stock exchange. The content is about share option grants, which relates to capital changes but is not a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the share options granted. The most appropriate classification is 'Share Issue/Capital Change' (SHA) because it concerns the issuance of share options, a form of capital change.
2021-10-25 English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF PATIENT ENROLLMENT IN A PHASE III CLINICAL TRIAL OF KN046 IN COMBINATION WITH CHEMOTHERAPY IN THE TREATMENT OF ADVANCED UNRESECTABLE OR METASTATIC SQUAMOUS NSCLC
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Alphamab Oncology regarding the completion of patient enrollment in a Phase III clinical trial for a drug candidate. It provides detailed information about the clinical trial, the drug, and the company's business focus. There are no financial statements, regulatory certifications, or voting results. The document is an operational update on clinical trial progress, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or a report publication announcement since it contains substantive business information rather than just announcing a report's availability. The content is best classified as a general regulatory announcement about business progress, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2021-10-15 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.